Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Inclusion Criteria:

• ≥ 18 years old
• Histologically confirmed renal cell carcinoma with clinically or pathologically confirmed progression
• Ineligible for interleukin-2 (IL-2) treatment and/or have had 2 or fewer prior treatments
• Measurable disease
• Hemoglobin ≥ 9 mg/dL
• ECOG performance status of 0, 1, or 2
• Willing and able to provide written informed consent

Exclusion Criteria:

• Inadequate bone marrow, renal and liver function by laboratory criteria

  • Absolute neutrophil count < 1500/µL;
  • Platelet count < 100,000/µL;
  • AST or ALT > 2 x upper limit of normal (ULN);
  • Alkaline phosphatase > 5 x ULN;
  • Total bilirubin > 2 x ULN;
  • Creatinine > 2.0 mg/dL.
• Evidence of central nervous system metastases within past year
• Uncontrolled hypertension
• Known history of porphyria, G6PD deficiency or HIV